Genenta Science (NASDAQ:GNTA) Posts Quarterly Earnings Results, Beats Expectations By $0.28 EPS

Genenta Science (NASDAQ:GNTA) announced its quarterly earnings data on Tuesday. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.28, FiscalAI reports.

Genenta Science Stock Performance

GNTA stock traded up $0.03 on Wednesday, hitting $0.70. 10,259 shares of the company were exchanged, compared to its average volume of 1,057,562. Genenta Science has a twelve month low of $0.59 and a twelve month high of $10.00. The business’s fifty day moving average is $0.92 and its two-hundred day moving average is $1.81.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Genenta Science in a research report on Friday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Trading of Genenta Science

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Ghisallo Capital Management LLC purchased a new position in shares of Genenta Science in the 4th quarter worth $482,000. Weiss Asset Management LP purchased a new stake in Genenta Science during the fourth quarter valued at about $480,000. Norges Bank purchased a new stake in Genenta Science during the fourth quarter valued at about $337,000. Alyeska Investment Group L.P. acquired a new stake in Genenta Science during the fourth quarter worth about $328,000. Finally, SmartHarvest Portfolios LLC purchased a new position in shares of Genenta Science in the 4th quarter worth about $26,000. 15.13% of the stock is currently owned by institutional investors and hedge funds.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.